Zasocitinib
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Zasocitinib
- Molecular weight
- 460.5
- Structure (SMILES)
- CNc1cc(Nc2cccn(-c3ccccn3)c2=O)nc2c(C(=O)N[C@@H]3CC[C@H]3OC)cnn12
- ndi 034858
- Ndi-034858
- NDI-034858
- ndi034858
- NDI034858
- tak 279
- Tak-279
- TAK-279
- tak279
- TAK279
- zasocitinib
- Zasocitinib
- ZASOCITINIB
- Zasocitinib (Dose A)
- zasocitinib [INN]
- ZASOCITINIB [USAN]
- Zasocitinib [WHO-DD]
- zasocitinib inn
- zasocitinib usan
- zasocitinib who dd
- CAS registry numbers
- 2272904-53-5
- ChEMBL ID
- CHEMBL5314423
- InChIKey
- BWINBHTTZLVXGT-NVXWUHKLSA-N
- PubChem compound IDs
- 137441492
- FDA ingredient codes (UNII)
- C293MNS6TQ
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- zasocitinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- tyrosine kinase 2
- Gene symbol
- TYK2
- Protein identifier
- P29597
- Median affinity
- 7
- Affinity units
- pIC50
- Condition
- Crohn Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000384
- Subject identifier
- D003424
- Condition
- Psoriasis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Colitis, Ulcerative
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000729
- Subject identifier
- D003093
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Arthritis, Psoriatic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003778
- Subject identifier
- D015535
- Condition
- Psoriasis
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001494
- Subject identifier
- D011565
- Condition
- Inflammation
- Highest recorded phase
- 2
- Condition identifier
- MP:0001845
- Subject identifier
- D007249
- Condition identifier
- EFO_0000384
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000676
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000729
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003778
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000710
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001494
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005011
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005083
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005101
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006559
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008661
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0011849
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0100491
- Highest recorded phase
- 3
- Condition identifier
- MP_0001845
- NCT04999839
- NCT05153148
- NCT05976321
- NCT05992155
- NCT06088043
- NCT06108544
- NCT06233461
- NCT06254950
- Hydrogen bond acceptors
- 10
- Hydrogen bond donors
- 3
- Polar surface area
- 127.47
- Calculated partition coefficient (ALogP)
- 1.97
- Calculated partition coefficient (XLogP)
- 1.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 7
- Heavy atoms
- 34
- Molecular formula
- C23H24N8O3
- Monoisotopic mass
- 460.19713666
- Natural product
- No
- Recorded assays
- 11
- Active assays
- 11
Active assay types
- Confirmatory
Related records
Trials (25)
- A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
- A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
- A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
- A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
- A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults
- A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
- A Study of TAK-279 in Adults With or Without Kidney Problems
- A Study of TAK-279 in Adults With or Without Liver Damage
- A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements
- A Study of TAK-279 in Healthy Chinese Adults
- A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
- A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults
- A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults
- A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease
- A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
- A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis
- A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
In development for (8)
- Crohn disease Phase 2
- Hidradenitis suppurativa Phase 2
- Kidney disorder Phase 1
- Liver disorder Phase 1
- Palmoplantar pustulosis Phase 3
- Psoriasis Phase 3
- Psoriatic arthritis Phase 2
- Ulcerative colitis Phase 2